Live Breaking News & Updates on சமிக்ஞை ஜெநெடிக்ஸ்

Stay updated with breaking news from சமிக்ஞை ஜெநெடிக்ஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Kintara Therapeutics Appoints - GuruFocus.com


SAN DIEGO, May 4, 2021
SAN DIEGO, May 4, 2021 /PRNewswire/ Kintara Therapeutics, Inc. (Nasdaq: KTRA) ( Kintara or the Company ), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Tamara A. Seymour to the Company s Board of Directors replacing John Liatos, who will continue in his role as Kintara s Senior Vice President of Business Development.
We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive, commented Saiid Zarrabian, Kintara s President and Chief Executive Officer. Tamara s insights and perspectives will be a valuable addition to the Board and the entire Company as we continue to advance our platform assets VAL-083 and REM-001. We wish to thank John for his service to the Board and are excited to continue working with him as the Company s Senior VP of Business Develop ....

United States , San Diego , La Jolla , Jules Abraham , John Liatos , Tamaraa Seymour , National Cancer Institute , Company Current Reports On Form , Company Quarterly Reports On Form , Company Annual Report On Form , Company Senior , Georgia State University , Audit Committee Of Artelo Biosciences Inc , Company Board Of Directors , Vital Therapies Inc , Valdosta State University , Genetics Inc , Favrille Inc , Business Administration , Business Development , Prnewswire Kintara Therapeutics Inc , Immunic Inc , Senior Vice President , Saiid Zarrabian , Chief Executive , Audit Committee ,

Global To Decide The Sustenance Quotient Of The Oligonucleotide Therapeutics Market – KSU


RNAi
Want a sneak peek into the Oligonucleotide Therapeutics market? Access the “Table of Content” of Oligonucleotide Therapeutics market report!  https://www.persistencemarketresearch.com/toc/12787
Oligonucleotide Therapeutics Market: Region-wise Outlook
The presence of the main market leaders, market consolidation and commercialization of new molecules are all contributing towards the dominating position of North America in the oligonucleotides therapeutic market. Miragen Therapeutics, Inc. agreed to merge with Signal Genetics, Inc for an initial investment of USD 40 million. Through this merger both the companies expect to develop micro RNA-targeted oligonucleotide clinical products. New molecule application is also another strategy the market players are using to mark their presence in the oligonucleotide therapeutic market. Biogen recently received FDA approval for a new drug application for nusinersen. If approved, the antisense oligonucleotides molecule wo ....

United States , Genetics Inc , Daiichi Sankyo Co Ltd , Capital Co Ltd , Miragen Therapeutics Inc , Mitsubishi Ufj , Innovation Network Corporation Of Japan , Disease Treatment Institute Co Ltd , Oligonucleotide Therapeutics , Therapeutics Market , North America , Signal Genetics , Innovation Network Corporation , ஒன்றுபட்டது மாநிலங்களில் , ஜெநெடிக்ஸ் இன்க் , தய்ச்சி சாங்கியோ இணை லிமிடெட் , மூலதனம் இணை லிமிடெட் , மிட்‌ஸ்யூபீஶி உப்ஜு , கண்டுபிடிப்பு வலைப்பின்னல் நிறுவனம் ஆஃப் ஜப்பான் , சிகிச்சை சந்தை , வடக்கு அமெரிக்கா , சமிக்ஞை ஜெநெடிக்ஸ் , கண்டுபிடிப்பு வலைப்பின்னல் நிறுவனம் ,